Enlivex Therapeutics Ltd
(ENLV)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 11,202 | 23,020 | 13,495 | 5,314 | 6,844 |
| Marketable Securities | 72,928 | 65,484 | 77,988 | 87,577 | 30,034 |
| TOTAL | $86,442 | $90,281 | $92,828 | $93,776 | $38,121 |
| Non-Current Assets | |||||
| PPE Net | 2,530 | 1,673 | 1,694 | 1,483 | 1,481 |
| Other Non-Current Assets | 6,174 | 6,213 | 665 | 703 | 756 |
| TOTAL | $8,704 | $7,886 | $2,359 | $2,186 | $2,237 |
| Total Assets | $95,146 | $98,167 | $95,187 | $95,962 | $40,358 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 878 | 1,062 | 558 | 347 | 463 |
| Accrued Expenses | 3,840 | 2,878 | 3,225 | 3,415 | 2,738 |
| Other current liabilities | N/A | 792 | 793 | 1,146 | 1,171 |
| TOTAL | $4,718 | $4,732 | $4,576 | $4,908 | $4,372 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 5,389 | 5,352 | 405 | 449 | 499 |
| TOTAL | $5,389 | $5,352 | $405 | $449 | $499 |
| Total Liabilities | $10,107 | $10,084 | $4,981 | $5,357 | $4,871 |
| Shareholders' Equity | |||||
| Common Shares | 2,107 | 2,107 | 2,104 | 2,104 | 1,646 |
| Retained earnings | -51,965 | -47,229 | -43,805 | -40,697 | -37,497 |
| Other shareholders' equity | 1,101 | 1,101 | 244 | -1,811 | 977 |
| TOTAL | $85,039 | $88,083 | $90,206 | $90,605 | $35,487 |
| Total Liabilities And Equity | $95,146 | $98,167 | $95,187 | $95,962 | $40,358 |